A pharmaceutical company has announced positive results from its phase Ib clinical study on its drug for neuropathic pain.
AlzeCure develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain. These latest results demonstrate that ACD440, a TRPV1 antagonist, could show positive proof-of-mechanism data, showing analgesic efficacy. The observed effects with ACD440 were highly significant over placebo. It was also well-tolerated as a topical gel on human skin, indicating suitability for further clinical development, i.e., a local treatment for neuropathic pain conditions.
Preparations are ongoing for further clinical trials with a planned Phase II trial by the end of 2021.